Human platelet lysate as an alternative to fetal bovine serum for culture and endothelial differentiation of human amniotic fluid mesenchymal stem cells
Tancharoen W., Aungsuchawan S., Pothacharoen P., Bumroongkit K., Puaninta C., Pangjaidee N.
Animal Study, published in Mol Med Rep (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mol Med Rep (2019)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 31059024
- PMCID
- PMC6522963
- DOI
- 10.3892/mmr.2019.10182
- Citations
- 24
Abstract (original English)
Human amniotic fluid (hAF) mesenchymal stem cells (MSCs) are commonly cultured in medium containing FBS. However, there are concerns about using animal serum in therapeutic applications due to the potential for immunogenic reactions and the risk of transmission of pathogens. For safety reasons, human platelet lysate (hPL) has been suggested as a replacement for FBS because it appears to be a natural source of growth factors. In this present study, it was investigated whether FBS could be substituted with hPL in hAF‑MSCs culture without affecting their properties. Pooled hPL was generated by the freeze‑thaw method. The concentration of hPL was selected after evaluation by MTT assay. The hAF‑MSCs were cultured in FBS‑ or hPL‑supplemented conditions and shared a fibroblast‑like morphology. Cell proliferation assays showed that the growth characteristic of hAF‑MSCs cultured in 10% hPL‑supplemented media was similar to those cultured in 10% FBS‑supplemented media. The expression of MSC markers did not differ between the cells cultured in the different conditions. The endothelial differentiation potential was also investigated. Reverse transcription‑quantitative (RT‑q)PCR revealed that induced cells supplemented with hPL showed an increase level of endothelial specific gene expression compared to the FBS‑supplemented cells. Immunofluorescence analysis showed specific protein localiza
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.